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ABSTRACT  
 
Soft tissue calcification is associated with aging, common conditions such as diabetes or 
hypercholesterolemia and with certain genetic disorders. ABCC6 is an efflux transporter 
primarily expressed in liver facilitating the release of ATP from hepatocytes. Within the liver 
vasculature, ATP is converted into pyrophosphate (PPi), a major inhibitor of ectopic 
calcification. ABCC6 mutations thus lead to reduced plasma PPi levels resulting in the 
calcification disorder pseudoxanthoma elasticum (PXE) and some cases of generalized arterial 
calcification of infancy (GACI). Most mutations in ABCC6 are missense and many 
retain/preserve transport activity but are retained intracellularly. We have previously shown that 
the chemical chaperone 4-phenylbutyrate (4-PBA) promotes the maturation of ABCC6 mutants 
to the plasma membrane. In a humanized mouse model of PXE, we investigated whether 4-PBA 
treatments could rescue the calcification inhibition potential of selected ABCC6 mutants. We 
used the dystrophic cardiac calcification (DCC) phenotype of Abcc6-/- mice as an indicator of 
ABCC6 function to quantify the effect of 4-PBA on human ABCC6 mutants transiently 
expressed in the liver. We showed that 4-PBA administrations restored the physiological 
function of ABCC6 mutants resulting in enhanced calcification inhibition. This study identifies 
4-PBA treatments as a promising strategy for allele-specific therapy of ABCC6-associated 
calcification disorders.  
 
 
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Pomozi et al, Functional rescue of mutant ABCC6 by 4-Phenylbutyrate 
 
 3 
INTRODUCTION  
 
Ectopic calcification is commonly associated with hypercholesterolemia, diabetes, chronic renal 
insufficiency and certain rare genetic diseases. ABCC6 is an organic anion transporter primarily 
present in the basolateral plasma membrane of hepatocytes (Pomozi et al., 2013). ABCC6 
deficiency is linked to several mineralization pathologies: pseudoxanthoma elasticum (PXE, 
OMIM 264800) is characterized by late onset and progressive calcifications in the skin leading to 
prominent dermal manifestations as well as in vascular and ocular tissues (Le Saux et al., 2000); 
β-thalassemia (OMIM 187550), which may be related to reduced levels of ABCC6 protein in the 
liver (Martin et al., 2011); and a subset of generalized arterial calcification of infancy (GACI, 
OMIM 208000), that is typically associated with ENPP1 mutations and results in early patient 
mortality (Nitschke et al., 2012). In several inbred strains of mice, including C3H/HeJ, ABCC6 
deficiency causes an acute calcification phenotype affecting the myocardium and the media of 
large arteries (Aherrahrou et al., 2008; Doehring et al., 2006; Meng et al., 2007). Because this 
peculiar phenotype occurs in response to a tissue injury, it is referred to as dystrophic cardiac 
calcification or DCC (Brampton et al., 2014). 
 
A recent metabolomics analysis revealed that ABCC6 facilitates the cellular efflux of nucleotide 
triphosphates, including ATP, which is rapidly converted into inorganic pyrophosphate (PPi) by 
the ectonucleotidase ENPP1 (Jansen et al., 2013). PPi is a potent inhibitor of ectopic calcification. 
ABCC6 is responsible for the majority of PPi release from the liver, and accounts for ~60% of 
PPi plasma levels in mice and humans (Jansen et al., 2014).    
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4-phenylbutyrate (4-PBA) is a short-chain fatty acid used in several clinical applications, 
including the treatment of urea cycle disorders, where it works as a nitrogen-scavenging 
molecule. 4-PBA also functions as a chemical chaperone and can correct the trafficking defects 
of misfolded proteins (Iannitti and Palmieri, 2011) including many transmembrane proteins 
associated with human diseases such as ABCC7, ABCA1 or ABCB11 (Gonzales et al., 2015; 
Hayashi et al., 2016; Rubenstein and Zeitlin, 2000; Sorrenson et al., 2013). As the majority of 
ABCC6 mutations are missense, we recently developed a methodology to investigate the 
functional consequences of these mutations on the human protein. In these studies a majority of 
ABCC6 missense mutants presented a transport activity similar to the wild type protein as 
determined by in vitro assays. However, most of these mutants presented abnormal cellular 
localization, failing to reach the plasma membrane both in cultured cells and mouse liver (Le 
Saux et al., 2011; Pomozi et al., 2014). The localization of the transmembrane ABCC6 protein 
into the basolateral plasma membrane is very relevant to its physiological function as an efflux 
transporter (Ilias et al., 2002; Le Saux et al., 2011; Pomozi et al., 2014; Pomozi et al., 2013). 
Treatment with 4-PBA significantly increased the plasma membrane localization for several 
transport-competent ABCC6 missense mutants in vitro and in vivo (Le Saux et al., 2011; Pomozi 
et al., 2014). 
 
In the present study, we addressed whether calcification inhibition could be restored in Abcc6-/- 
mice expressing human ABCC6 mutants in their liver and treated with 4-PBA.  
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RESULTS 
 
We and others have previously reported that 4-PBA administration rescued the plasma 
membrane targeting of several human ABCC6 mutants in wild type mice (Aranyi et al., 2013; 
Jin et al., 2015; Le Saux et al., 2011; Pomozi et al., 2014). In this study, we transiently expressed 
four ABCC6 missense mutants in the liver of Abcc6-/- mice and confirmed that these variants 
were also successfully routed back to the plasma membrane after 4-PBA injections (Fig. 1) using 
a methodology we previously described (Le Saux et al., 2011; Pomozi et al., 2014). Furthermore, 
we verified that 4-PBA redirected a representative ABCC6 mutant (p.Q1347H) to the basolateral 
compartment of the plasma membrane of hepatocytes, which is the normal location of both 
human and mouse ABCC6 (Pomozi et al., 2013; Scheffer et al., 2002; Sinko et al., 2003). For 
these control experiments, we used immunofluorescent staining to examine the co-localization of 
the p.Q1347H mutant and the wild type ABCC6 (as a control) with basolateral (Na-taurocholate 
co-transporting polypeptide (NTCP) and cadherin) and apical markers, (ABCB11) with and 
without 4-PBA treatments. Co-localization was quantified on immunofluorescent images using 
ImageJ2 (Schindelin et al., 2012) by calculating Pearson’s correlation coefficients between 
mutant and wild type ABCC6 and both basolateral markers. We found that, in the absence of 4-
PBA treatment, the p.Q1347H mutant showed a predominant intracellular staining with a clear 
demarcation from NTCP and cadherin. After 4-PBA treatment however, the immunofluorescent 
staining pattern of the p.Q1347H mutant became similar to that of both basolateral markers with 
a significant increase of the Pearson’s correlation coefficients (Fig. 2A, B, D, E), indicating that 
the wild type and 4-PBA-treated mutant primarily localize in the basolateral plasma membrane 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Pomozi et al, Functional rescue of mutant ABCC6 by 4-Phenylbutyrate 
 
 6 
compartment. Moreover, we observed very little evidence, if any, of co-localization of the wild 
type and the p.Q1347H mutant (with and without 4-PBA treatment) with the ABCB11 in the 
apical compartment of the plasma membrane and the corresponding Pearson’s correlation 
coefficients values were close to 0 (Fig. 2C, F). Collectively, these data indicate that upon 4-
PBA treatment, the ABCC6 mutant p.Q1347H assumes a normal and physiological plasma 
membrane localization. 
 
Several years ago, Abcc6 was linked to DCC in several inbred strain of mice carrying a naturally 
occurring Abcc6 mutation (Aherrahrou et al., 2008; Meng et al., 2007). Although, 3 additional 
loci affecting the penetrance and expression of DCC were mapped to chromosomes 4, 12, and 14 
(Ivandic et al., 2001), ABCC6 is the major determinant of this cardiac calcification phenotype 
(Aherrahrou et al., 2007; Korff et al., 2006a; Korff et al., 2006b). Moreover, we have shown that 
in Abcc6-/- mice the hepatic expression of ABCC6 has a predominant influence on the 
development of DCC (Brampton et al., 2014). Therefore, to determine if 4-PBA could restore the 
calcification inhibition potential of ABCC6 mutants, we quantified DCC as a measure of ABCC6 
function. With this approach we first determined that the expression of the unrelated LacZ gene 
(Fig. 3A) or 4-PBA treatment by itself (not shown) had no significant influence on DCC in 
Abcc6-/- mice. After having established a baseline of DCC reduction (-66%, p=0.0001) using the 
wild type human ABCC6, we evaluated the effects of 4-PBA treatments in mice expressing 4 
human disease-causing ABCC6 variants (Fig. 3A), which were chosen based on our previous 
results (Le Saux et al., 2011; Pomozi et al., 2014). The hepatic expression of the mutants alone 
provided no calcification inhibition. However, the concomitant administration of 4-PBA, led to 
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 7 
significant DCC reduction for 3 of the variants: p.R1314W (-62.8%, p=0.0045), p.Q1347H (-
64.2%, p=0.0005), and p.S1121W (-45.0%, p=0.045). Note that p.R1314W is an ABCC6 
mutation common to PXE and GACI. The reduction in dystrophic calcification associated with 
these mutants was comparable to the wild-type human ABCC6 protein (p=0.62). The 4-PBA 
treatment of the p.R1114P mutant resulted in some calcification inhibition that did not reach 
statistical significance (p=0.10). Because most PXE patients are diagnosed during the second 
decade of life, with a calcification phenotype already developed, we addressed the question of 
whether established ABCC6-dependent calcification could also be reversed after restoring 
ABCC6 function with 4-PBA treatment. For this purpose, we have injected the p.Q1347H 
mutant in Abcc6-/- mice and started 4-PBA administration 36 hours after induction of DCC by 
cryoinjury, at a time when calcification is well-developed (Korff et al., 2006a). The results, 
shown on Fig. 3B, indicated that the restoration of ABCC6 function after cryionjury could not 
reverse existing calcification. 
 
To confirm DCC quantification data, which only measured excess calcium in heart tissues, visual 
and histological characterization of cardiac calcification was assessed at the time of dissection by 
the presence of white deposits at the site of injury (Fig. 4A) and by Alizarin Red staining on 
paraffin-embedded sections (Fig. 4B). Results showed reduced mineralization in mice expressing 
the wild type ABCC6 and a comparable reduction for the representative p.Q1347H mutant after 
4-PBA treatment which is consistent with calcification quantifications. 
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As ABCC6 function facilitates the release of nucleosides triphosphates, and particularly ATP, 
which is quickly converted into PPi in the liver vasculature (Jansen et al., 2014; Jansen et al., 
2013), we assayed plasma PPi levels of mice expressing the p.Q1347H mutant, which produced 
the most significant DCC rescue (Fig. 3). After several attempts in two different laboratories 
using various methodologies previously described (Jansen et al., 2014; Jansen et al., 2013), we 
were unable to detect significant change in plasma PPi levels (not shown). Therefore, we 
evaluated the effect of 4-PBA treatment on PPi production by the p.Q1347H mutant in HEK293 
cells. Interestingly, the transfection with the mutant protein led to an increase in PPi 
concentration in the supernatant over baseline levels (empty vector). This was not surprising as 
we previously found that ABCC6 missense mutants translocate to the plasma membrane more 
efficiently in non-polarized cells in culture than in vivo (Pomozi et al., 2014). The addition of 
5mM of 4-PBA in the culture medium had little effects on HEK293 cells transfected with an 
empty vector whereas it triggered a 64% increase (p=0.03) in PPi release into the supernatant of 
transfected cells (Fig. 5). This result confirmed that 4-PBA restored the function of the 
p.Q1347H and probably that of the others mutant (Fig. 3, 4), and provides support to our 
speculation that the chaperone effects of this drug rescued some of the ABCC6-mediated PPi 
production. 
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DISCUSSION 
 
Although palliative treatment exists for PXE patients (Finger et al., 2011), both PXE and GACI 
are still incurable diseases. PPi has a short half-life in plasma and there is currently no 
administration protocol available for this molecule for long-term therapy. Bisphosphonates, non-
hydrolysable analogs of PPi, were tested in GACI (Otero et al., 2013) and in Abcc6-/- mice (Li et 
al., 2015). Early treatments improve GACI outcome but Etidronate has undesirable side-effects 
(Otero et al., 2013). Moreover, bisphosphonates have pleiotropic effects on cellular functions and 
the large doses of Etidronate necessary in Abcc6-/- mice to achieve modest effects (Li et al., 
2015) suggest these analogs may not be the best treatment option. Another approach at rescuing 
the common ABCC6 R1141X variant using the drug PTC-124 has been tested in mice (Zhou et 
al., 2013) but because this premature stop codon is recoded as amino acids other than the original 
arginyl residue, its translational value remains unclear. 
 
There is now a growing interest in developing and testing a pharmacological correction for 
mutated transmembrane proteins. Developing new drugs for humans is a long and costly process, 
and generally unattractive for orphan diseases. One current and very promising trend to 
circumvent this problem is to re-purpose existing drugs and using them towards pathologies not 
initially identified for these drugs. 4-PBA has been used for many years for the clinical treatment 
of urea cycle disorders and thalassemia (Dover et al., 1992; Maestri et al., 1996; Perrine et al., 
1993). 4-PBA also influences the transcription of endoplasmic reticulum chaperones (Iannitti and 
Palmieri, 2011) and this physiological property has been used to treat patients with familial 
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intrahepatic cholestasis type 2 caused by ABCB11mutations that result in intracellular retention 
of an otherwise functional protein (Gonzales et al., 2012; Gonzales et al., 2015; Hayashi et al., 
2016; Naoi et al., 2014). In the present study, the doses of 4-PBA used in our humanized mouse 
model of PXE were similar to those used clinically (Maestri et al., 1996) and successfully 
restored the calcification inhibition potential of 3 selected ABCC6 missense mutants. However, 
for one of the 4 mutants (p.R1114P), the rescue of calcification inhibition was only minimal 
despite normal transport activity and plasma membrane localization after 4-PBA treatment 
(Pomozi et al., 2014). This suggested that the arginine to proline substitution might have 
compromised other essential functions of the protein, such as substrate specificity, and illustrates 
some limitations to the applicability of 4-PBA to rescue ABCC6 missense mutations. 
 
Although we evidenced the positive effect of 4-PBA on the correct plasma membrane targeting 
of ABCC6 mutants and PPi production in cell culture, we could not detect a similar rise in 
pyrophosphate in murine plasma samples.  This may be explained by the methodologies 
employed in our study. Unlike human PXE patients who express mutant ABCC6 in all of their 
hepatocytes, the hydrodynamic tail vein injections used in our study only results in partial and 
transient transfection (Brampton et al., 2014; Jiang et al., 2010). Considering the inherent 
difficulties of measuring PPi in biological fluids (O'Neill et al., 2010; Russell et al., 1971) and its 
short half-life (O'Neill et al., 2011),  it is therefore, possible that the peak of PPi production was 
below our detection levels. Furthermore, a facet of ABCC6 physiological function could not be 
evaluated in this study as the substrate(s) that ABCC6 (potentially) efflux is still unknown 
(Jansen et al., 2013) and there may be alternative molecular mechanism(s) other than 
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pyrophosphate by which ABCC6 prevents ectopic calcification. Another limitation of our 
experimental model is that the functional rescue (inhibition of calcification) was not complete. 
This could be due to the fact that we have restored the cellular localization and the physiological 
activity of the protein only in liver. The liver has the highest levels of ABCC6 expression but 
several other tissues and cells also express the protein (Beck et al., 2005; Beck et al., 2003; 
Douet et al., 2007) and these could contribute significantly to calcification inhibition. However, 
the effect of 4-PBA on calcification inhibition in human would most likely surpass that obtained 
with our humanized mouse model as PXE patient express ABCC6 in all liver hepatocytes and 
other tissues.  
 
In conclusion, our study demonstrated the viability of using 4-PBA to rescue the functional 
defects of certain ABCC6 missense mutations and restore their calcification inhibition potential. 
This interpretation is restricted to the ABCC6 variants studied and the restoration of their 
physiological function as determined by injury-induced DCC, which is distinct from the typical 
PXE phenotype; we could not assess the PXE-like spontaneous calcification of Abcc6-/- mice 
because of our experimental settings. However, based on our results, we propose that 4-PBA 
treatments could serve as an allele-specific therapy for PXE/GACI. Approximately 75% of 
PXE patients harbor at least one missense allele and many of these patients carrying missense 
mutants with residual transport activity could be eligible for 4-PBA treatment. As PXE and 
GACI are recessive diseases, the rescue of single missense allele should be sufficient. 
Therefore, if 4-PBA treatment is eventually used to treat PXE patients, one will have to define 
which clinical criteria to use to assess treatment efficacy. Moreover, because we found that 4-
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PBA treatment of ABCC6 mutations prevents but does not reverse mineralization, the sooner 
treatment is initiated, the better.  
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MATERIAL AND METHODS 
 
The experiments described in this manuscript were conducted at the University of Hawaii and 
Hungarian Academy of Sciences following identical experimental protocols so that results from 
one laboratory were systematically duplicated and verified in the other facility and later 
integrated. The results shown on Figure 1 and 4 were obtained at the University of Hawaii. The 
results of Figure 2 and 5 were primarily generated at Hungarian Academy of Sciences. Figure 3 
was developed at the University of Hawaii with contribution from the Hungarian Academy of 
Sciences. 
 
Animals 
C57BL/6J mice, designated here as wild type were derived from mice purchased from The 
Jackson Laboratory. Abcc6tm1Aabb mice were generated on 129/Ola background (Gorgels et al., 
2005) and backcrossed into a C57BL/6J >10 times. These mice are herein designated Abcc6-/-. 
Both male and female, 3 to 4 month-old age-matched Abcc6-/- and wild type mice were used, as 
gender had no significant influence on our previous results. All animals were housed in approved 
animal facilities at the University of Hawaii School of Medicine and the Research Center for 
Natural Sciences, Hungarian Academy of Sciences. Mice were kept under routine laboratory 
conditions with 12-hours light-dark cycle, a constant temperature of 23˚C and with ad libitum 
access to water and chow in similar facilities at the University of Hawaii and Hungarian 
Academy of Sciences. The University of Hawaii and Hungarian Academy of Sciences 
Institutional Animal Care and Use Committees approved this study. Experiments have been 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Pomozi et al, Functional rescue of mutant ABCC6 by 4-Phenylbutyrate 
 
 14
conducted according to national guidelines. 
 
Immunodetection 
Liver-specific expression of ABCC6 variants in mice and immunohistochemical staining were 
performed as described in a previous study (Le Saux et al., 2011). Briefly, after mouse 
euthanasia, multiple liver lobes were quickly harvested, placed in Optimum Cutting 
Temperature (OCT) compound and stored at -80˚C. Immunofluorescent staining was 
performed on 6 µm-thick frozen sections. The rat monoclonal anti-ABCC6 M6II-31 antibody 
(sc-59618) was used to specifically detect the human ABCC6. The anti-Abcb11 antibody and 
anti-Ntcp antibody were gifts from Dr. Bruno Stieger (Univ. Zurich, Switzerland). The rabbit 
polyclonal anti-Cadherin antibody was purchased from Abcam (Cambridge, MA). The rabbit 
polyclonal S-20 anti-Abcc6 antibody (sc-5787) was used to verify the absence of the 
endogenous protein in Abcc6-/- mice as we have already demonstrated the specificity of this 
antibody on frozen liver sections and isolated primary hepatocytes from Abcc6-/- mice, (Le 
Saux et al., 2011; Pomozi et al., 2013). These primary antibodies were purchased from Santa 
Cruz Biotechnology (Santa Cruz, CA). The secondary antibodies were Alexafluor 488 and 568 
(Life Technologies, CA). Immunofluorescent images were acquired with a Zeiss LSM 710 
confocal laser scanning microscope. For evaluation of co-localization, individual images of 
cells for the ABCC6 Q1347H mutant were collected and processed with Photoshop CS6 
(Adobe, San Jose, CA). The Pearson’s correlation coefficient was calculated using the ImageJ2 
software (Schindelin et al., 2012) using the Coloc 2 tool. 
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Liver-specific expression of ABCC6 cDNA in mice  
Inducing the transient expression of a specific cDNA by hydrodynamic tail vein injection has 
been described previously (Alino et al., 2003; Le Saux et al., 2011; Liu et al., 1999; Zhang et al., 
1999; Zhang et al., 2004). Briefly, cDNAs encoding the wild type and several variants of the 
human ABCC6 or the β-galactosidase were sub-cloned into the pLIVE vector carrying the mouse 
albumin promoter and a fetoprotein enhancer that ensured a liver-specific expression (Mirus Bio, 
Madison, WI). Plasmid DNA constructs were delivered to 3-month old Abcc6-/- mice by 
hydrodynamic tail vein injection. The injections were performed with a 27-gauge needle with a 
volume of 1.5 to 2ml of DNA in a solution of TransIT EE® according to the manufacturer’s 
instruction (Mirus Bio Madison, WI). Mice were injected with the optimal dosage of 30 to 60 µg 
of plasmid, as previously defined (Le Saux et al., 2011).  
 
Myocardial cryoinjury to induce DCC 
Cardiac injury was instilled through trans-diaphragm cryoinjury as previously described 
(Brampton et al., 2014). Mice were sacrificed by CO2 asphyxiation 7 days after injury to ensure 
full DCC development. Hearts were quickly removed, rinsed in phosphate buffered saline, 
imaged and either minced and placed in a 0.15N HCl solution to quantify calcium content (see 
below) or paraffin-embedded for histology analysis with Alizarin Red staining.  
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Calcification measurements 
The level of mineralization in the whole ventricular area of the hearts minus the atria was 
quantified with a colorimetric assay (McGee-Russell, 1958) that measures directly the amount of 
excess calcium, which is then normalized to the weight of the excised tissues, as previously 
described (Brampton et al., 2014). Briefly, hearts were minced and decalcified for 48 hours in 
0.15N HCl and the total calcium content of the supernatant was assessed using the Calcium 
(CPC) Liquicolor kit (Stanbio). Calcium content was expressed in µg/dL and per milligram of 
tissue.  
 
4-PBA administration 
The procedure for intraperitoneal injections and oral dosage of 4-PBA followed a method 
adapted from previously described protocol (Pomozi et al., 2014). Mice typically received 
intraperitoneal injections of 4-PBA (1000 mg/kg/day) 24 hours before hydrodynamic tail vein 
injections, however, for the calcification reversal experiments, mice were administered 4-PBA 
36 hours after cryoinjury. Injection were continued daily thereafter until euthanasia. In addition, 
drinking water contained 6.25 mg/ml 4-PBA to ensure continuous exposure to the drug. 
 
Cell culture 
HEK 293H cells were stably transfected with a plasmid carrying a cDNA encoding the ABCC6 
Q1347H mutant or with an empty vector as transfection controls using standard techniques. 
Transfected cells were seeded onto 12-well plates and grown to confluency. Cells were then 
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incubated with 800µl fresh DMEM medium (containing or not 5mM 4-PBA) for 24 hrs. PPi 
concentration was determined in harvested media. 
 
Pyrophosphate measurements 
PPi in plasma (harvested 24 and 48 hours post hydrodynamic tail vein injections) and culture 
supernatant were determined as previously described in (Jansen et al., 2013) and (Jansen et al., 
2014) respectively. 
 
Data analysis 
Data were compared by the Student t test. Values are expressed as mean +/- standard error of the 
mean (SEM). A p value <0.05 was considered statistically significant. Animal numbers used for 
individual set of data varied and is shown on the figures. The authors take full responsibility for 
the integrity of the data and all authors have read and agree to the manuscript as written. 
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FIGURE LEGENDS 
 
Figure 1: Intracellular localization of human ABCC6 variants expressed in Abcc6-/- mice. 
Hydrodynamic tail vein injections led to the successful expression of human wild type and 
mutant ABCC6. ABCC6 was detected on liver frozen sections by immunofluorescence using 
the M6II-31 monoclonal antibody (green) to verify the plasma membrane localization with or 
without 4-PBA treatments. Co-labeling with the S-20 polyclonal antibody (red) was used to 
control for the absence of the endogenous mouse Abcc6 and wild type mice (Abcc6+/+) were 
used as positive controls. DAPI was used as counter staining (blue). With 4-PBA treatments, 
ABCC6 mutant proteins were predominantly located in the plasma membrane. Scale bar = 
50µm. 
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Figure 2: The human ABCC6 variant p.Q1347H localizes to the basolateral membrane of 
Abcc6-/- mice treated with 4-PBA. Liver frozen sections were used to perform 
immunofluorescent co-labeling between ABCC6 (green) and the basolateral markers (B) 
cadherin and (B) Na-taurocholate co-transporting polypeptide (NTCP), as well as (C) the apical 
marker (ABCB11) (red) to determine the plasma membrane localization. DAPI was used as 
counter staining (blue). To estimate co-localization between the normal and mutant ABCC6 and 
cadherin (D), NTCP (E) and ABCB11 (F), a Pearson’s correlation coefficient was calculated 
(ImageJ2) from sets of individual immunofluorescence images from animals with or without 4-
PBA treatment. With 4-PBA treatments, the representative ABCC6 mutant p.Q1347H showed 
enhanced co-localization with the basolateral markers while no evidence of co-localization is 
seen with ABCB11 in the apical membrane. Scale bar = 20µm. Results for panels D-F are 
shown +/- SEM. * p<0.05, ** p<0.01, *** p<0.001. 
 
Figure 3: 4-PBA treatments rescue ABCC6 function. A: The wild type ABCC6 protein, four 
PXE/GACI mutants and LacZ were transiently expressed in Abcc6-/- liver prior to inducing 
dystrophic cardiac calcification (DCC). Abcc6-/- mice were exposed to 4-PBA for 7 days 
(controls received saline injections) with a cumulative dose of 1,000 mg/kg/day. The level of 
calcification (DCC phenotype) was measured as total heart calcium content and normalized to 
tissue weight. B: The p.Q1347H variant was transiently expressed in Abcc6-/- liver prior to 
inducing dystrophic cardiac calcification (DCC). Abcc6-/- mice were administered 4-PBA 36 hrs 
after DCC induction (controls received saline injections) until the harvesting of hearts. The 
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level of calcification (DCC phenotype) was measured as total heart calcium content and 
normalized to tissue weight. Results are +/- SEM. * p<0.05, ** p<0.01.  
 
Figure 4: Histological evaluation of dystrophic cardiac calcification (DCC) of Abcc6-/- mice.  
After excision, hearts were fixed in formalin and paraffin embedded. Sections were stained with 
Alizarin Red S and imaged. A: representative images obtained with Abcc6-/- mice illustrate the 
macroscopic appearances of the surface lesions outlined with a dashed circle. The calcification is 
visible as white deposits. B: microscopic images of heart cross sections of Abcc6-/- mice show the 
reduction of dystrophic cardiac calcification (Red deposits and white arrows) after expression of 
the p.Q1347H mutant and 4-PBA treatment. The expression of the gene LacZ and the wild type 
ABCC6 were used as negative and positive controls respectively. Scale bars = 200 µm. 
 
Figure 5: Effect of 4-PBA on PPi production in vitro. HEK293 cells were transfected with a 
plasmid carrying a cDNA encoding the ABCC6 mutant p.Q1347H or with an empty vector as 
transfection control. The presence of 5mM of 4-PBA in the culture medium resulted in a 
significant increase in PPi production suggesting the restoration of p.Q1347H cellular function. 
Results are +/- SEM, * p<0.05, n.s. = not significant. 
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